	US 11,891,447 B2
	Method for treating cancer using CD14 antagonists
Huei-Wen Chen, Taipei (TW); Pan-Chyr Yang, Taipei (TW); and Wan-Jiun Chen, Taipei (TW)
Assigned to NATIONAL TAIWAN UNIVERSITY, Taipei (TW)
Appl. No. 16/637,093
Filed by Huei-Wen Chen, Taipei (TW)
PCT Filed Aug. 9, 2018, PCT No. PCT/CN2018/099617 § 371(c)(1), (2) Date Feb. 6, 2020, PCT Pub. No. WO2019/029617, PCT Pub. Date Feb. 14, 2019.
Claims priority of provisional application 62/543,067, filed on Aug. 9, 2017.
Prior Publication US 2020/0181279 A1, Jun. 11, 2020
Int. Cl. A61K 39/00 (2006.01); C07K 16/00 (2006.01); C07K 16/28 (2006.01); A61P 35/00 (2006.01); A61K 38/00 (2006.01)

CPC C07K 16/2896 (2013.01) [A61P 35/00 (2018.01); A61K 38/00 (2013.01); A61K 39/00 (2013.01); A61K 2039/505 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01)]

12 Claims

1. A method for treating cancer, comprising:

administering to a subject in need thereof an effective amount of a CD14 antagonist, wherein the subject is a human subject having cancer;

wherein the CD14 antagonist is effective in reducing stemness of cancer stem cells (CSCs) in the human subject having cancer;

wherein the human subject having cancer has an elevated level of CD14, an elevated level of programmed death ligand-1 (PDL1), and an elevated level of CD44, as compared to a control human subject not having cancer;

wherein the cancer is lung cancer;

wherein the CD14 antagonist is an anti-CD14 antibody;

wherein the anti-CD14 antibody is an antigen-binding fragment thereof; and

wherein the anti-CD14 antibody comprises six complementarity determining regions (CDRs) of anti-hCD14-IgA2 antibody, clone D3B8.